Company Overview and News

 
Cadila Healthcare: A pain reliever

2018-09-15 premium.thehindubusinessline
Indian pharmaceutical companies seem to be finally turning the corner, bringing relief to investors. Improving financials due to subsiding pricing pressure in the US, coupled with recovering domestic business, have meant better prospects for the firms. Though it appears that the worst is behind them, the recovery seems to be gradual for these companies, given the lower generic opportunity in the US, rising competition and continuing regulatory overdrive on domestic plants.
532321 CDLYY CADILAHC

 
An evening walk down Dalal Street | Photo finish on D-Street! Sensex ends over 350 points higher, Nifty races past 11,500

2018-09-14 moneycontrol
It’s a perfect photo finish for D-Street! The Nifty raced past 11,500 and ended the session above that mark. This is contrary to the negative moves that the market had in the first couple of days of the week.
SPARC 524715 BHRQY 532843 533278 AKLD CADILAHC CDLYY 532454 532872 532321 FORTIS SUNPHARMA 500477 BHARTIARTL AKLS CLNDY COALINDIA ASHOKLEY

 
Cadila Healthcare rises nearly 3% as co receives USFDA final approval

2018-09-14 moneycontrol
Share price of Cadila Healthcare rose nearly 3 percent intraday Friday as Zydus Cadila has received the final approval from the USFDA to market Risedronate Sodium Delayed-Release Tablets, 35 mg.
532321 CDLYY CADILAHC

 
Cadila Healthcare Limited - Press Release

2018-09-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532321 CDLYY CADILAHC

 
Company news: Zydus Cadila

2018-09-11 thehindubusinessline
Zydus Cadila has received tentative approval from the United States Food and Drug Administration (USFDA) for Sitagliptin tablets for sale in the US markets in strengths of 25 mg, 50 mg and 100 mg. In a filing to the exchanges, the company said the drug will be produced at the group’s formulations facility at SEZ, Ahmedabad. The group has more than 217 approvals, and has so far, filed over 330 abbreviated new drug applications.
532321 CDLYY CADILAHC

 
Indian pharma market grew 8.7% in August on slower offtake of anti-infectives

2018-09-11 moneycontrol
The Indian pharmaceutical market (IPM) grew at 8.7 percent in August, much slower than in July due to lacklustre sales of anti-infective drugs, according to market research firm AIOCD-AWACS.
532321 CDLYY CADILAHC

 
Cadila Healthcare Limited - Press Release

2018-09-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532321 CDLYY CADILAHC

1
Deals Buzz: Jet Airways loyalty arm sale to be managed by Moelis

2018-09-05 livemint
Jet Airways has finalised boutique investment bank Moelis & Co. to manage a stake sale in Jet Privilege, the loyalty rewards programme that the carrier co-owns with Etihad Airways, The Economic Times reported. The report added that private equity giants TPG and Blackstone were vying for the sale. Mint first reported on 20 August that TPG has entered the race to buy the stake, competing with Blackstone.
IAUGY 532321 IAUGF IAG 532617 JETAIRWAYS CG CADILAHC CDLYY

 
Zydus Cadila gets USFDA nod for herpes viruses treatment drug

2018-09-05 moneycontrol
Drug firm Zydus Cadila Wednesday said it has received final approval from the US health regulator to market Acyclovir injecion, used to treat infections caused by herpes viruses, in the US market.
532321 CDLYY CADILAHC

 
D-Street Buzz: Nifty pharma outperforms with Sun Pharma up 2%; RIL advances, Advanced Enzyme jumps 9%

2018-09-05 moneycontrol
The Indian benchmark indices are trading on a flat to positive note this Wednesday morning with the Nifty50 trading at 11,521, up 1 point while the Sensex is trading higher by 38 points at 38,196.
ESL SUZLON MUTHOOTFIN 500325 AUROPHARMA RELIANCE 533398 TATACOMM 532733 CADILAHC CSLQY 532321 532221 SONATSOFTW RIGD AJANTPHARM 520086 GAILF BEL SUEL SUNTV RLNIY 500870 BHQRY 524804 533264 532667 CDLYY CASTROLIND 532331 ARBQY GAILY SICAL SNQVY 500049 500483

 
Cadila Healthcare rises 2% on USFDA final approval for antiviral drug

2018-09-05 moneycontrol
Share price of Cadila Healthcare rose 2.6 percent intraday Wednesday on the back of USFDA approval for Acyclovir sodium injection.
532321 CDLYY CADILAHC

 
Cadila Healthcare Limited - Press Release

2018-09-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532321 CDLYY CADILAHC

28
Your Daily Scoop: Anifrolumab Flunks, Aquestive Approved, Vertex's CRISPR Trial In Germany

2018-09-03 seekingalpha
Discussion: AstraZeneca (AZN) announced failure of a Phase 3 trial of its anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus (‘SLE). The drug failed to achieve a statistically valid reduction in disease activity at month 12 as measured by a scale called SRI4. Reduction in SRI4 value was the primary endpoint of the trial. Shares slipped marginally by 1% in the negative news.
VRTX QDEL AQST AZN PTLA AUPH ARWR CRSP GSK CADILAHC CDLYY MYL 532321 AUP AZN IMMU BMS JNJ BGNE NVS

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 006378905